Dec. 1 at 10:43 PM
$RVPH $RVPH $ACAD $AXSM $AUPH $IBRX
Check out this- RVPH is trading as penny stock with some major do or die type fda meetings coming up in December.
+ ves: Their trial data is very positive so far.. schizophrenia treatment market alone represents an
$13.4B opportunity. ABBV paid
$9B for a clinical trial drug that later failed. These guts are trading at 40-50m mkt cap.
risks- high dilution risk.. reverse split, nasdaq compliance risk etc looms..
From today’s Benita article- RVPH Reviva’s breakthrough medication Brilaroxazine has been shown to have improved broad spectrum efficacy and treatment adherence with reduced side effects in both acute and stable schizophrenia patients in well-controlled clinical trials compared to historical data reported for widely used standard of care antipsychotics.
Reviva has planned meetings with the FDA to discuss Brilaroxazine’s path forward to approval in Q4 2025, and a New Drug Application (NDA) submission targeted for Q2 2026.
